Hussein Mirna, Essam Safia, Mekky Mennatullah Essam, Ahmed Lujaina, Farouk Heidi Sherif, Alshanshoury Batool Sami, Gado Jana, El-Masry Hassan, Gaber Hamed
Faculty of Medicine, Alexandria University, Khartoum Square, Alexandria, 21526, Egypt.
Probiotics Antimicrob Proteins. 2025 May 5. doi: 10.1007/s12602-025-10544-z.
Food allergies are common, affecting a sizable portion of children and adults in the Western world. In recent years, a promising treatment known as allergen immunotherapy (AIT) has emerged. This technique aims to address the fundamental immune system dysfunction that underlies food allergies. The study's objective was to evaluate the safety of combining probiotics with AIT, compared to placebo in treating patients with food allergies. A comprehensive literature search in several databases was conducted. All included studies were randomized controlled trials(RCTs). Meta-analyses were performed using R software. Statistical tests to assess safety outcomes and risk of bias were used. After reviewing 519 studies, three studies were included in the systematic review and meta-analysis, involving a total of 258 patients (141 in the probiotics group, 144 in the placebo group). The evaluation of the safety profile of the integrated probiotic therapy revealed an overall favorable outcome, with no significant differences in adverse events compared to placebo for most organ systems examined. However, a potential increase in oral adverse effects was observed in the probiotics group (RR = 1.7573, 95% CI: 0.3941 to 7.8359), although this result did not reach statistical significance. The combination of probiotics and allergen-specific immunotherapy appears to be generally safe and shows promise as a valuable treatment approach.
食物过敏很常见，影响着西方世界相当一部分儿童和成人。近年来，一种名为变应原免疫疗法（AIT）的有前景的治疗方法出现了。这项技术旨在解决食物过敏背后的根本免疫系统功能障碍。该研究的目的是评估在治疗食物过敏患者时，将益生菌与AIT联合使用与安慰剂相比的安全性。在几个数据库中进行了全面的文献检索。所有纳入的研究均为随机对照试验（RCT）。使用R软件进行荟萃分析。采用统计检验来评估安全性结果和偏倚风险。在审查了519项研究后，三项研究被纳入系统评价和荟萃分析，共涉及258名患者（益生菌组141名，安慰剂组144名）。对综合益生菌疗法安全性的评估显示总体结果良好，在所检查的大多数器官系统中，与安慰剂相比，不良事件无显著差异。然而，在益生菌组中观察到口腔不良反应有潜在增加（RR = 1.7573，95% CI：0.3941至7.8359），尽管这一结果未达到统计学显著性。益生菌与变应原特异性免疫疗法的联合应用似乎总体安全，显示出作为一种有价值治疗方法的前景。
